Single Dose Escalation Study of CM383 in Healthy Volunteers

Summary

This study is a single center, randomized, double-blind, placebo-controlled Phase I clinical study in a single dose escalation to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in male healthy subjects.

Timeline

Start

2024-05-28

Primary completion

2025-06-30

Completion

2025-06-30

Drugs

Indications